Skip to main content
. 2023 Oct 16;18:326. doi: 10.1186/s13023-023-02925-w

Fig. 2.

Fig. 2

One-way sensitivity analysis in all randomized patients. A All randomized patients, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin, PFS Progression-free survival, PD Progressive disease, WTP Willingness to pay, EV Average value, QALY Quality-adjusted life year